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Background: Although Clostridium difficile is a major cause of diarrhoea, its epidemiology in tropical settings is
poorly understood. Strain characterisation requires work-up in specialised laboratories, often after prolonged
storage without properly maintained cold chain.
Methods: We screened 298 human faecal samples from Coˆte d’Ivoire using a rapid test for C. difficile glutamate
dehydrogenase (GDH). GDH-positive samples were aerobically stored at disrupted cold chain conditions (mean
duration: 11 days) before transfer to a reference laboratory for anaerobic culture, susceptibility testing, PCR
assays and ribotyping.
Results: Sixteen samples (5.4%) had a positive GDH screening test. C. difficile infection was confirmed in six speci-
mens by culture and PCR, while no nucleic acids of C. difficile were detected in the culture-negative samples.
Further analysis of stool samples harbouring toxigenic C. difficile strains confirmed that both GDH and toxins
remained detectable for at least 28 days, regardless of storage conditions (aerobic storage at 48C or 208C).
Conclusions: Storage conditions only minimally affect recovery of C. difficile and its toxins in stool culture. A rapid
GDH screening test and subsequent transfer of GDH-positive stool samples to reference laboratories for in-depth
characterisation may improve our understanding of the epidemiology of C. difficile in the tropics.
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Introduction
Clostridium difficile is an anaerobic, Gram-positive, rod-shaped
and endospore-forming bacterium that may survive under
extreme environmental conditions, including high temperatures,
toxic chemicals and UV radiation.1 C. difficile is the leading
cause of nosocomial, antibiotic-associated diarrhoea worldwide
and there is growing evidence that C. difficile is also a key patho-
gen of community-acquired intestinal infections.2–5 While a
steady increase of C. difficile-associated diarrhoea (CDAD) has
been observed in Europe and North America, there is a paucity
of epidemiological data from Africa, Asia6 and South America7
where diarrhoeal diseases remain important causes of morbidity
and mortality.8 For example, a search on PubMed/Medline on
June 23, 2015 using the search strategy ‘Clostridium difficile
AND Africa’ yielded only 29 hits, 15 studies of which pertained
to the bacterium’s prevalence in humans, animals or environmen-
tal samples from Africa.9–23
Recent data suggest that CDAD in travellers returning from
low- and middle-income countries is considerable, thus highlight-
ing the need to deepen our understanding of the epidemiology of
C. difficile in Africa and elsewhere in the developing world.24
Additionally, there is ongoing debate whether C. difficile might
be regularly transmissible as a zoonotic disease via animals or
food products. Zoonotic transmission to humans has been docu-
mented for some strains (e.g., ribotype [RT] 078), but no direct
food-borne outbreaks have been reported thus far.25,26 Strains
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sequence typing28 or other genotypic methods.29,30 Some hyper-
virulent RTs (e.g., RT027) are reported to be associated with a
more severe clinical disease, but no data on the currently circulat-
ing RTs have been reported from Africa.31
The paucity of epidemiological data from resource-constrained
settings is explained by the cumbersome laboratory diagnosis of
C. difficile, which has led to its scientific neglect in many tropical
areas. Comprehensive diagnostic work-up requires cultural growth
of C. difficile on selective media under anaerobic conditions, fol-
lowed by subsequent molecular typing in specialised laboratories.
It follows that testing strategies for C. difficile vary considerably
even in high-income countries. Indeed, a recent multicentre
study estimated that approximately 40 000 hospitalised patients
with C. difficile infection remain undiagnosed every year in Europe
due to the use of insensitive laboratory diagnostic tests.32 In con-
trast, not even the most basic diagnostic tests for C. difficile are
available in many resource-constrained settings. One of the few
recent studies pertaining to the clinical relevance of this pathogen
stems from Zimbabwe; C. difficile was detected in 8.6% of patients
with community-acquired diarrhoea,22 which underscores the
need for an improved understanding of its occurrence in Africa.
Rapid diagnostic tests (RDTs) for C. difficile have been devel-
oped and constitute a useful screening tool to provide point-
of-care information, particularly in resource-constrained settings.
In common diagnostic algorithms, a C. difficile-specific glutamate
dehydrogenase (GDH) assay is employed as a first-line test to
identify specimens that warrant further diagnostic work-up.33,34
Though GDH is specific for C. difficile, it does not differentiate
pathogenic toxigenic strains from apathogenic non-toxigenic
strains. Some rapid membrane tests combine GDH screening
with testing for toxins A and B, but the sensitivity of toxin detec-
tion is low.35 A thorough assessment of GDH-positive samples
includes an array of sophisticated tests, including anaerobic toxi-
genic culture, followed by genotypic and phenotypic characterisa-
tion. While the pure confirmation of C. difficile infection and a
differentiation between toxigenic and non-toxigenic strains is pos-
sible by stool-based PCR alone, a culture isolate is required for PCR
ribotyping and antimicrobial susceptibility testing.
In resource-constrained settings, the transfer of GDH-positive
samples to reference laboratories within a country or abroad may
take several days. Hence, it is important to understand whether and
how prolonged storage, transport conditions, environmental fac-
tors and varying temperatures affect the recovery of C. difficile in
stool samples. Thus far, it is widely believed that a sensitive diagno-
sis needs to be performed on fresh stool samples due to the
instability of C. difficile antigens. Indeed, the Association for
Professionals in Infection Control and Epidemiology (APIC) currently
recommends that samples should be frozen at –708C if testing can-
not be performed within 24 hours after stool collection.36 However,
storage under controlled freezing conditions is limited in most
developing countries.
We conducted a case-control study in south Coˆte d’Ivoire to
investigate the epidemiology and diagnostic accuracy of different
methods for detection of intestinal pathogens. In this manuscript,
we report on the frequency and characterisation of C. difficile
strains using a two-step diagnostic algorithm consisting of a
GDH screening test, followed by comprehensive sample work-up
in a specialised laboratory after prolonged specimen storage at
disrupted cold chain conditions. Moreover, we examined the influ-
ence of a prolonged storage under standardised aerobic
conditions at varying temperatures on the detection of C. difficile
using toxigenic culture and molecular diagnostic techniques.
Materials and methods
Study area and population
The study was conducted in October 2012 in Dabou and 11
surrounding villages, located some 30 km west of Abidjan, the eco-
nomic capital of Coˆte d’Ivoire. The study was part of a site assess-
ment to identify a suitable setting in Coˆte d’Ivoire for a subsequent
multi-country investigation on the aetiology of persistent diarrhoea
and persistent abdominal pain.37,38 This research is coordinated by
the European research network with the acronym NIDIAG, which
aims to develop simple and cost-effective diagnosis-treatment
algorithms for three clinical syndromes (i.e., digestive syndromes,
persistent fever and neurological disorders) in tropical set-
tings.33,38–41 In the site assessment reported here, a case-control
approach was adopted. Hence, individuals aged≥1 year presenting
with persistent diarrhoea (≥2 weeks) and individuals without any
gastrointestinal symptoms (control group) were invited to partici-
pate. Definitions put forth by WHO were used to define diarrhoea,
i.e., the passing of three or more loose stools within 24 hours.38 The
prevalence of various diarrhoeagenic bacteria, helminths, intestinal
protozoa and viruses in cases and matched controls has been pre-
sented elsewhere.37
Field and laboratory procedures
Fresh stool samples were obtained in the early morning and trans-
ferred to the local hospital laboratory in Dabou. Upon arrival, an
RDT indicating the presence of GDH (Clostridium K-SeT, Coris
BioConcept, Gembloux, Belgium)42 was performed to screen for
C. difficile. Additionally, several microscopic techniques were
employed for the diagnosis of intestinal protozoa and helminth
infections (i.e., Baermann funnel, formalin-ether concentration
technique, Kato-Katz thick smear and Koga agar plate).37
For later confirmatory testing of C. difficile in a specialised labora-
tory, approximately 0.3 g of each stool sample was transferred into
a small vial and aerobically stored under ‘real life conditions’ in a
fridge without proper maintenance of the cold chain due to power
cuts. After a storage period between 8 and 19 days (mean 11 days),
the samples were transferred at ambient temperature to the
German National Advisory Laboratory for C. difficile in Homburg,
Germany. All GDH-positive stool samples were analysed for the pres-
ence of C. difficile by anaerobic culture on a selective solid medium
(CLO agar, BioMe´rieux, Marcy l’E´toile, France), and by multiplex PCR of
stool samples (GenoType CDiff, Hain Lifescience, Nehren, Germany).
The multiplex PCR detects the following C. difficile-associated genes:
gluD (encoding for GDH), tpi (encoding for triose phosphate isomer-
ase), tcdA (encoding for toxin A), tcdB (encoding for toxin B) and
cdtA/B (encoding for the binary toxin). Additionally, characteristic
deletions in the regulatory gene tcdC and resistance to moxifloxacin
(mutations in the gyrA gene) are detected. The PCR assay was
regarded as the internal diagnostic reference standard in our
study due to stability of culture-independent assays, and results
obtained by anaerobic stool culture after the prolonged sample stor-
age were compared to this method. Suspected culture-grown col-
onies were identified based on typical morphology and distinct
odour. Diagnosis of C. difficile was subsequently confirmed by
matrix-assisted laser desorption ionisation time-of-flight mass
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spectrometry (MALDI-TOF MS with BioTyper software, Bruker
Daltonics, Bremen, Germany). Phenotypic characterisation was per-
formed by antimicrobial susceptibility testing using Etests (metro-
nidazole, moxifloxacin and vancomycin) and disk diffusion assay
(clarithromycin and rifampicin), according to previously described
standard protocols.32,43 Species-specific EUCAST breakpoints (http://
www.eucast.org) were used, if available.44 PCR ribotyping using
capillary gel electrophoresis was performed in Homburg, Germany
to achieve genotypic differentiation and the results were independ-
ently confirmed in Leiden, The Netherlands. Files of untypeable C. dif-
ficile strains with previously undescribed ribotype patterns were also
sent to Leeds University, UK for analysis using an in-house database.
To further analyse the influence of storage conditions on the
performance of diagnostic tests, ten stool samples stemming
from symptomatic, hospitalised patients with laboratory-proven
toxigenic C. difficile infections were prospectively collected at
the Saarland University Medical Center in Homburg, Germany.
The faecal samples were split into two aliquots and stored in
parallel at 48C and at 208C (ambient temperature) for at least
28 days. Diagnostic testing for C. difficile using toxigenic culture
and an RDT for detection of GDH and toxins A/B (C. Diff Quik
Check Complete, Alere, Ko¨ln, Germany) was repeated after 7, 14
and 28 days. The resulting RDT line intensities were documented
using a semi-quantitative grading scheme, i.e., 3+, strong;
Figure 1. Study flowchart on the occurrence of Clostridium difficile in 298 individuals in Dabou, south Coˆte d’Ivoire, in October 2012. GDH: glutamate
dehydrogenase; RDT: rapid diagnostic test.
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2+, moderate; 1+, faint; and –, negative. The culture isolates of C.
difficile were further characterised by PCR-based detection of
toxin genes and ribotyping.
Statistical analysis
Data of the RDT screening results in Coˆte d’Ivoire and of subse-
quent laboratory procedures were entered twice and cross-
checked in Excel version 14.0 (edition 2010, Microsoft Corp.,
Redmond, WA, USA). Analysis of C. difficile-specific RT patterns
was performed using the software BioNumerics version 7.1 (edi-
tion 2013, Applied Maths, Sint-Martens-Latem, Belgium). In
brief, a Dice similarity coefficient and the unweighted pair group
method with arithmetic mean (UPGMA) algorithm were employed
to compare closely related C. difficile isolates and to infer their
genetic relatedness.
Ethics statement
The study protocol was approved by the institutional research
commissions of the Swiss Tropical and Public Health Institute
(Swiss TPH, Basel, Switzerland) and the Centre Suisse de
Recherches Scientifiques en Coˆte d’Ivoire (CSRS; Abidjan, Coˆte
d’Ivoire). Study approval was given by the Directorate of the
Hoˆpital Me´thodiste in Dabou. The study is registered on Current
Controlled Trials (http://www.controlled-trials.com; identifier
ISRCTN86951400). Individuals aged above 12 months with resi-
dency in Dabou or surrounding villages with written informed
consent (parents/guardians signing for individuals aged below
18 years) were eligible to participate.
Results
The study flowchart is shown in Figure 1. In brief, GDH RDTs were
performed on 298 stool samples for screening of C. difficile directly
on site. Sixty-eight samples were provided by individuals with per-
sistent diarrhoea (≥2 weeks) and 230 specimens originated from
individuals without diarrhoea (asymptomatic controls). Positive
test results were found on 16 samples. Four faecal specimens
stemmed from symptomatic patients with persistent diarrhoea
(5.8%). Of these, two patients stated to have received antibiotic
treatment with cotrimoxazole and metronidazole, respectively,
in the two preceding months. The remaining 12 RDT-positive sam-
ples were found in healthy controls (5.2%). Of note, samples
with a faintly discernible test band were also considered as
GDH-positive to increase the sensitivity of the screening test
(Figure 2).
Fifteen GDH-positive samples were available for subsequent
culture and molecular diagnosis in a European reference labora-
tory. Anaerobic culture yielded six C. difficile isolates which were
independently confirmed by direct stool-based PCR. No specific
DNA of C. difficile could be amplified in the nine culture-negative
samples, thus leading to a 100% concordance between stool cul-
ture and direct molecular testing. Among the six isolates, none
was a toxigenic strain, as determined by toxigenic culture and
PCR for tcdA (toxin A), tcdB (toxin B) and cdtA/B (binary toxin).
Four C. difficile isolates originated from individuals without gastro-
intestinal disorders (1.7%), while two isolates stemmed from
symptomatic patients with persistent diarrhoea (2.9%). The dif-
ference between cases and matched controls was not statistically
significant (Fisher’s exact test, p¼0.622) and the lack of toxin
production excludes C. difficile as causative agent in the two
symptomatic patients.
We assessed all GDH-positive isolates for parasitic co-infections.
An infection with intestinal protozoa or helminths was found in five
out of nine RDT-positive and culture-negative samples (three
Endolimax nana, one Giardia intestinalis, one triple infection with
E. nana, Entamoeba coli and hookworm). Among the six culture-
positive C. difficile samples, only one parasitic co-infection
was detected (triple infection with Blastocystis spp., E. coli and
Entamoeba hartmanni).
The genotypic differentiation of the six C. difficile isolates via
ribotyping determined one isolate as RT199 and one isolate as
RT390, while the patterns of the remaining four C. difficile isolates
differed from those of the .500 previously described RTs. Hence,
these isolates could not be typed in Homburg, Leiden and Leeds
and represent new RTs. A dendrogram (Figure 3) depicts the spe-
cific ribotyping patterns of these C. difficile isolates from Coˆte
d’Ivoire in comparison to some closely related RTs. Details on
the antimicrobial susceptibility of all isolates are presented in
Table 1.
Additionally, ten toxigenic C. difficile isolates originating from
clinically relevant infections of hospitalised patients in Homburg
were analysed to assess the influence of storage conditions on
antigen detection and culture of preserved stools. All samples,
whether stored at 48C or 208C, tested positive for both GDH and
toxins after 7, 14 and 28 days, and C. difficile could always be
recovered in toxigenic culture during the study period. In some
samples, there was a trend towards reduced signal intensities of
RDT after prolonged storage, and this observation was slightly
more pronounced if stool samples were stored at ambient tem-
perature. However, C. difficile RDTs are designed as qualitative
assays, and both GDH and toxins remained detectable in all
stool samples. Stability of testing after prolonged storage of
Figure 2. Results given by the rapid diagnostic glutamate dehydrogenase
(GDH) screening test (Clostridium K-SeT) employed for diagnosis of
Clostridium difficile in Dabou, south Coˆte d’Ivoire in October 2012:
negative, faintly positive and strongly positive.
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stool samples was confirmed for a variety of clinically important
ribotypes (Table 2).
Discussion
Our results indicate that the two-step diagnostic algorithm with a
point-of-care GDH screening on the spot, followed by prolonged
storage under disrupted cold chain conditions and subsequent
sample transfer to a reference laboratory for selective anaerobic
stool culture and PCR ribotyping is feasible to investigate C. difficile
in faecal samples obtained from resource-constrained settings.
Importantly, stool culture results were not affected by prolonged
storage (up to 19 days) under aerobic atmosphere and varying,
non-standardised temperature conditions. Cultural growth
of C. difficile was observed in all PCR-confirmed specimens, thus
showing an excellent agreement between both methods and
confirming the stability of infectious spores of C. difficile over pro-
longed time periods. Additional experiments performed on stool
samples stemming from hospitalised patients with toxigenic
C. difficile infections in Germany further underscored our findings,
as both GDH and toxins remained detectable in the stool over a
period of at least 28 days, regardless of storage conditions.
The use of GDH RDT is an easily applicable, rapid and sensitive
tool to screen for C. difficile infection and is suitable for use in
remote and resource-constrained settings. It is thus of particular
importance in areas where prompt diagnosis is crucial and more
sophisticated laboratory work-up is not feasible.45 Notably, of 15
GDH-positive stool samples in our study, only six revealed C. diffi-
cile by culture. However, even samples with a faintly positive test
band in the RDT for GDH were included for further diagnostic
work-up to maximise the diagnostic sensitivity of the initial
screening, acknowledging that this strategy might decrease the
specificity of the RDT. On the other hand, we cannot exclude
that low amounts of C. difficile may indeed have been present in
these culture-negative samples, and unfavourable storage condi-
tions (intermittent cold chain, no preservation medium) might
have negatively influenced the recovery of bacteria.46 However,
our finding that all culture-negative samples were also negative
for C. difficile when employing a stool-based PCR strongly suggests
false-positive RDT results as the more likely explanation for this
discrepancy.
Figure 3. Dendrogram showing the specific ribotype (RT) profiles of six Clostridium difficile isolates from Dabou, south Coˆte d’Ivoire, obtained in October
2012, in comparison to related RTs, as determined by capillary ribotyping. Ribotyping displays a high diversity of the isolates. The dendrogram was
generated by the software BioNumerics version 7.1 (edition 2013, www.applied-maths.com).
Table 1. Genotypic and phenotypic characterisation of Clostridium difficile isolates from Dabou, south Coˆte d’Ivoire, obtained in October 2012. PCR
ribotyping, toxigenic culture and antimicrobial susceptibility testing (S, susceptible; R, resistant) were performed. The results of toxigenic culture
were independently confirmed by multiplex PCR for toxin genes (tcdA, tcdB and cdtA/B). The minimal inhibitory concentration (MIC, expressed as
mg/ml) is given, if susceptibility testing was performed by Etest
Antimicrobial susceptibility testing (MIC, expressed as mg/ml)
C. difficile Ribotype Toxigenic culture Metronidazole Vancomycin Moxifloxacin Clarithromycin Rifampicin
Isolate 1 New (unknown) Non-toxigenic S (0.5) S (1.0) S (1.5) R S
Isolate 2 New (unknown) Non-toxigenic S (0.75) S (0.5) S (1.5) S S
Isolate 3 RT199 Non-toxigenic S (0.5) S (0.5) S (1.0) S S
Isolate 4 New (unknown) Non-toxigenic S (0.75) S (0.75) S (1.5) S S
Isolate 5 RT390 Non-toxigenic S (0.5) S (0.5) S (1.5) R S
Isolate 6 New (unknown) Non-toxigenic S (0.75) S (0.75) S (1.5) R S
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When using an RDT, the resulting line intensity can vary and
pale, weak lines may lead to false-positive results. Guideline sys-
tems on how to read test results in a reliable, standardised way
have been developed e.g., for malaria RDTs, and may also be use-
ful to objectify the interpretation of C. difficile-specific RDTs.47 With
regard to its use as a first-line screening test, the Clostridium K-SeT
RDT showed moderate specificity in this study, which underscores
the need for a confirmatory test to avoid false-positive results.48
Moreover, GDH assays cannot discriminate between toxigenic and
non-toxigenic infections. However, new research has elucidated
that asymptomatic C. difficile carriage per se profoundly alters
the intestinal microbial diversity,49 and further studies assessing
this infection in both asymptomatic carriers and symptomatic
patients from tropical settings will provide additional insights
into the pathogenesis of CDAD.
An optimisation of the culture-based recovery of C. difficile from
human stool has been identified as an important research need for
epidemiological studies.50 However, only few investigations have
Table 2. Results of a stool-based rapid diagnostic test (RDT) detecting Clostridium difficile glutamate dehydrogenase (GDH) and toxin A/B,
employed on stool samples from symptomatic patients and performed after prolonged aerobic storage at 48C and 208C over a storage period of 28
days. Resulting RDT line intensities are presented using a semi-quantitative grading scheme: 3+, strong; 2+, moderate; 1+, faint; –, negative
Sample Ribotype Toxin genes Day 0 Day 7 Day 14 Day 28
1 001 tcdA, tcdB GDH RDT (48C) 3+ 3+ 3+ 3+
GDH RDT (208C) 3+ 3+ 3+ 3+
Toxin RDT (48C) 3+ 3+ 2+ 2+
Toxin RDT (208C) 3+ 3+ 2+ 1+
2 005 tcdA, tcdB GDH RDT (48C) 3+ 3+ 3+ 3+
GDH RDT (208C) 3+ 3+ 3+ 2+
Toxin RDT (48C) 2+ 2+ 1+ 1+
Toxin RDT (208C) 2+ 2+ 1+ 1+
3 005 tcdA, tcdB GDH RDT (48C) 3+ 3+ 2+ 2+
GDH RDT (208C) 3+ 3+ 2+ 2+
Toxin RDT (48C) 3+ 3+ 2+ 2+
Toxin RDT (208C) 3+ 3+ 2+ 2+
4 011 tcdA, tcdB GDH RDT (48C) 3+ 3+ 3+ 3+
GDH RDT (208C) 3+ 3+ 3+ 3+
Toxin RDT (48C) 2+ 2+ 1+ 1+
Toxin RDT (208C) 2+ 1+ 1+ 1+
5 013 tcdA, tcdB GDH RDT (48C) 3+ 3+ 3+ 3+
GDH RDT (208C) 3+ 3+ 3+ 3+
Toxin RDT (48C) 1+ 1+ 1+ 1+
Toxin RDT (208C) 1+ 1+ 1+ 1+
6 014 tcdA, tcdB GDH RDT (48C) 3+ 3+ 3+ 3+
GDH RDT (208C) 3+ 2+ 2+ 2+
Toxin RDT (48C) 3+ 3+ 1+ 1+
Toxin RDT (208C) 3+ 1+ 1+ 1+
7 017 tcdA, tcdB GDH RDT (48C) 3+ 3+ 3+ 3+
GDH RDT (208C) 3+ 3+ 3+ 2+
Toxin RDT (48C) 2+ 2+ 2+ 2+
Toxin RDT (208C) 2+ 2+ 2+ 2+
8 027 tcdA, tcdB, binary toxin GDH RDT (48C) 3+ 3+ 3+ 3+
GDH RDT (208C) 3+ 3+ 3+ 3+
Toxin RDT (48C) 3+ 3+ 3+ 3+
Toxin RDT (208C) 3+ 3+ 3+ 3+
9 029 tcdA, tcdB GDH RDT (48C) 3+ 3+ 3+ 3+
GDH RDT (208C) 3+ 3+ 3+ 3+
Toxin RDT (48C) 3+ 3+ 3+ 3+
Toxin RDT (208C) 3+ 3+ 3+ 3+
10 029 tcdA, tcdB GDH RDT (48C) 3+ 3+ 3+ 3+
GDH RDT (208C) 3+ 3+ 3+ 3+
Toxin RDT (48C) 3+ 3+ 3+ 2+
Toxin RDT (208C) 3+ 3+ 3+ 2+
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addressed this issue with conflicting results, and most studies did
not employ independent molecular testing to elucidate ambiguous
results obtained by culture and RDT. In contrast to our findings, a
previous study reported a rapid decrease in the recovery rate of
C. difficile from 26 equine samples kept under aerobic conditions
with no C. difficile isolate being culturally detectable after 12 days
of aerobic storage at 48C, whereas all isolates could still be recov-
ered when stored anaerobically.51 Another study found that the
recovery of C. difficile on selective culture is only minimally affected
by storage conditions, whereas toxins in the stool samples rapidly
become undetectable after repeated freezing at –208C.52 A
Canadian study reported no influence of temperature and storage
conditions on the recovery of C. difficile kept over a period of
8 weeks.53 This finding is in agreement with our results and may
be explained by the bacterium’s characteristic formation of durable
endospores that persist in the environment before germinating
again under optimised growth conditions. Future investigations
should thus include environmental examinations and assess the
effects of appropriate selective media that may facilitate the con-
version from durable C. difficile endospores into the vegetative, cul-
tivable form after prolonged storage.
Our study has several limitations. First, the low number of posi-
tive samples limits the generalisability of our findings. Second,
none of the C. difficile strains in Coˆte d’Ivoire was toxigenic.
However, we tried to address these constraints by the additional
analysis of toxigenic isolates from clinically relevant infections
from Homburg. In all samples, the prolonged storage did not
negatively impact on the diagnostic yield of C. difficile stool cul-
ture, which underscores the reproducibility of our approach.
Third, also healthy controls were tested in our study for the pres-
ence of C. difficile, despite many clinical guidelines stating that
only symptomatic patients should be tested.3,34 While this is
true for clinical settings, investigations on the bacterium’s occur-
rence in the environment, animals and healthy humans will con-
tribute to an improved understanding of the largely unknown
epidemiology of C. difficile in Africa. Indeed, a recent study from
Coˆte d’Ivoire showed the presence of C. difficile in 12.4% of cooked
beef meat sold by street vendors in Abidjan.21
Conclusions
A two-step diagnostic approach consisting of GDH screening on
site, followed by in-depth genotypic and phenotypic characterisa-
tion in specialised laboratories is a promising strategy to investi-
gate C. difficile in tropical settings. The recovery of C. difficile in
human faecal samples from Coˆte d’Ivoire remained unaffected
by prolonged storage and transport conditions that lacked stand-
ardisation and cold chain. This observation is of considerable
importance for resource-constrained settings where accurate
diagnosis cannot be ascertained and stool samples might be
transported over several days to specialised laboratories. The pre-
sent pilot study identified only non-toxigenic apathogenic iso-
lates, both in symptomatic cases and matched asymptomatic
controls. Further studies are warranted to deepen our knowledge
of the transmission patterns, strain diversity and clinical relevance
of C. difficile in the humid tropics. Our results should also encour-
age surveillance studies to CDAD on the African continent to
obtain more insights into the global epidemiology of C. difficile
infections.
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